MedTrace Logo

Comparison of Lormetazepam and Midazolam Used as Sedatives for Patients That Require Intensive Care

NCT02022592 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2022-04-13

No results posted yet for this study

Summary

A goal directed , demand-driven administration of sedative drugs is an integral part of every intensive care treatment. During long-term application of sedatives, Midazolam is the most commonly used sedative in Europe.

One major objective is the problem of oversedation and agitation during an intensive care treatment due to the lack of controllability of available substances.

The Love-Mi RCT investigates the clinical controllability of Midazolam versus the newly available intravenous drug Lormetazepam.

Conditions

  • Sedation in Intensive Care Unit Patients

Interventions

DRUG

Lormetazepam

DRUG

Midazolam

Sponsors & Collaborators

  • Claudia Spies

    lead OTHER

Principal Investigators

  • Claudia Spies, MD, Univ.- Prof. · Charite University, Berlin, Germany

  • Gernot Marx, MD, Univ.-Prof. · University RWTH Aachen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-17
Primary Completion
2019-12-12
Completion
2020-03-12

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02022592 on ClinicalTrials.gov